Farnesyltransferase inhibitor therapy in acute myelogenous leukemia.

  title={Farnesyltransferase inhibitor therapy in acute myelogenous leukemia.},
  author={Jason R. Gotlib},
  journal={Current hematology reports},
  volume={4 1},
Acute myelogenous leukemia (AML) remains a clinical challenge with poor long-term survival. Low remission rates and high treatment-related mortality persist as major obstacles, particularly in older patients. The design of novel agents based on the identification of genetic lesions and aberrant signaling pathways provides opportunity to improve the standard treatment paradigm of intensive cytotoxic chemotherapy. Farnesyltransferase inhibitors (FTIs) show potential to fill this niche. The… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 15 extracted citations

A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2014

Similar Papers

Loading similar papers…